AveXis, Inc. logo

AveXis, Inc.

Research & development of technology for disease treatment, with our first work being in spinal muscular atrophy (SMA), an orphan disease. AveXis (Nasdaq:AVXS) is a clinical-stage gene therapy company developing treatments for rare and life-threatening neurological genetic diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.avexis.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
2275 Half Day Road, Suite 200, IL 60015
Bannockburn
United States
Email
Contact Number
+1 847-572-8280
+1 844-428-3947

AveXis (Nasdaq:AVXS) is a clinical-stage gene therapy company developing treatments for rare and life-threatening neurological genetic diseases.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/avexis-inc-” connections=”true” suffix=””]

The company utilizes a synthetic biology platform using gene therapy techniques that include adeno-associated virus (AAV) to develop new gene therapy techniques.

In May2018, AveXis Acquired by Novartis AG for $8.7 billion for $218 per share.

March 2018, AveXis Enters into an exclusive, worldwide license agreement with Genethon for in vivo gene therapy delivery of AAV9 vector into the central nervous system (CNS) for the treatment of spinal muscular atrophy (SMA).

Jan 2018, AveXis Announces Closing of Public Offering of Common Stock of 4,509,840 shares and Full Exercise of Underwriters 588,240 shares Option to Purchase Additional Shares. At a price to the public of $102.00 per share

In 2014, REGENX granted AveXis an exclusive, worldwide license, with rights to sublicense, to REGENXs NAV rAAV9 vector for treatment of SMA disease in humans. In return for these rights, REGENX receives an up-front payment, certain milestone fees and royalties on net sales of products incorporating NAV rAAV9.vectors.

In Jun 2015 Asklepios BioPharmaceutical and AveXis, entering into a license agreement, which grants AveXis rights to AskBios proprietary self-complementary (SC) technology, also known as Duplex vectors. This technology is utilized in AveXis Phase I Adeno-Associated Virus (AAV) gene transfer clinical trial in SMA1 patients. Financial details remains undisclosed.

In Feb 2016, AveXis raised $95 Mn through IPO. Prior that in 2015 company it raised $65 Mn in Series D round and $10 Mn in Series C round financing. Key Investors includes Venrock, Janus Capital, RA Capital, Foresite Capital Deerfield Management and Roche Venture Fund.